Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture.

Area of Science:

• Oncology
• Medical Imaging
• Biomarker Discovery

Background:

• Personalized medicine in oncology relies on identifying diagnostic, prognostic, or predictive biomarkers.
• Biomarkers now encompass complex physiological characteristics beyond traditional ex vivo measurements.
• Positron-emission-tomography (PET) imaging offers non-invasive in vivo characterization of tumor heterogeneity.

Purpose of the Study:

• To review evidence supporting PET imaging of tumor heterogeneity as a crucial tool in oncology.
• To highlight the role of PET-derived biomarkers in clinical decision-making for cancer treatment.
• To explore PET-based strategies for patient stratification and therapy selection.

Main Methods:

• Assessment of tumor heterogeneity using tracer uptake, such as 18F-fluoro-deoxyglucose (FDG).
• Utilizing multiple radiopharmaceuticals to gather diverse information about tumor characteristics.
• Reviewing existing clinical evidence on the application of PET imaging in oncology.

Main Results:

• PET imaging effectively characterizes tumor heterogeneity in vivo non-invasively.
• Measurement of tumor heterogeneity provides essential information for treatment strategy.
• PET-derived biomarkers aid in selecting patients for intensive or targeted therapies.

Conclusions:

• PET imaging of tumor heterogeneity is vital for personalized oncology.
• This approach enhances patient selection for tailored treatment strategies.
• PET biomarkers improve clinical decision-making in cancer care.